-

09:31:11 AM

ABBV Stock News

ABBV - Abbvie Inc

07/20/21 8:30 AM

NYSE : ABBV

conferences

Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting

Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) Annual Meeting being held July 23-27

RHEA-AI

neutral

07/16/21 8:30 AM

NYSE : ABBV

AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) did not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental New Drug Application (sNDA) for RINVOQ ® (upadacitinib) for the treatment of

RHEA-AI

neutral

07/07/21 8:00 AM

NYSE : ABBV

conferencesearnings

AbbVie to Host Second-Quarter 2021 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its second-quarter 2021 financial results on Friday, July 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through

RHEA-AI

neutral

06/29/21 8:00 AM

NYSE : ABBV

clinical trial

Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients

AbbVie (NYSE: ABBV) today announced that upadacitinib (15 mg or 30 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all secondary endpoints at one-year (week 52) in the Phase 3 ulcerative colitis

RHEA-AI

neutral

06/28/21 8:45 AM

NYSE : ABBV

AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO)

AbbVie today announced new data on upadacitinib (RINVOQ ®) in ulcerative colitis and risankizumab (SKYRIZI ®) in Crohn's disease will be presented as oral presentations at the 16 th Congress of European Crohn's and Colitis Organisation (ECCO), to

RHEA-AI

neutral

06/25/21 8:30 AM

NYSE : ABBV

AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action dates for the supplemental New Drug Applications (sNDAs) for

RHEA-AI

neutral

06/25/21 2:30 AM

NYSE : ABBV

CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis

AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of RINVOQ ® (upadacitinib), an oral, selective and reversible JAK

RHEA-AI

neutral

06/24/21 8:00 AM

NYSE : ABBV

acquisition

AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

AbbVie (NYSE: ABBV) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of

RHEA-AI

neutral

06/17/21 6:29 PM

NYSE : ABBV

dividends

AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share.The cash dividend is payable August 16, 2021 to stockholders of record at the close of business on July 15, 2021.Since the company's

RHEA-AI

neutral

06/12/21 7:02 AM

NYSE : ABBV

clinical trial

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study

AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® (ibrutinib) plus VENCLEXTA ® /VENCLYXTO ® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O)

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 8 9 10 Next

ABBV Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.abbvie.com
CeoRichard Gonzalez
Security nameAbbvie Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1 N Waukegan Rd
StateIllinois
CityNorth Chicago
Zip60064-1802
CountryUS
Phone18479327900

ABBV Description:

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.